Relationships of indicators such as level of plasma lipoprotein-associated phospholipase A2 with effect of extracorporeal counterpulsation therapy in high-risk patients with coronary heart disease

CHEN Haiyan; FU Xiaodan; ZHANG Qiuju

doi:10.7619/jcmp.20214222

Journal of Clinical Medicine in Practice > 2022 > 26(3): 63-67. > DOI: 10.7619/jcmp.20214222

CHEN Haiyan, FU Xiaodan, ZHANG Qiuju. Relationships of indicators such as level of plasma lipoprotein-associated phospholipase A2 with effect of extracorporeal counterpulsation therapy in high-risk patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 63-67. DOI: 10.7619/jcmp.20214222

Citation:

PDF (893 KB)

Relationships of indicators such as level of plasma lipoprotein-associated phospholipase A2 with effect of extracorporeal counterpulsation therapy in high-risk patients with coronary heart disease

Department of Cardiology, Dongguan Binhaiwan Central Hospital of Guangdong Province, Dongguan, Guangdong, 523900

More Information

Received Date: October 26, 2021
Available Online: March 10, 2022
Published Date: February 14, 2022

Graphical Abstract

Abstract

Abstract

Objective To study changes of plasma lipoprotein associated phospholipase A2 (Lp-PLA2), soluble lipoprotein receptor-associated protein 1 (sLRP-1), visfatin in high-risk patients with coronary heart disease and their effects on the outcomes of enhanced external counterpulsation therapy.
Methods A total of 94 patients with high risk of coronary heart disease admitted to our hospital were selected as observation group, and 80 healthy subjects in our hospital during the same period were selected as control group. Plasma Lp-PLA2, sLRP-1, visfatin, blood lipid indicators[triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)] and cardiac color Doppler ultrasound results [left ventricular ejection fraction (LVEF), left ventricular fractional shortening (FS), left ventricular end-diastolic diameter (LVDd)] were compared, and the diagnostic value of serum Lp-PLA2, sLRP-1 and visfatin in patients with high risk of coronary heart disease was evaluated. The observation group was divided into remission group and non-remission group according to the outcome of enhanced external counterpulsation therapy, and the relationships of plasma Lp-PLA2, sLRP-1, visfatin with treatment outcomes were analyzed.
Results Plasma Lp-PLA2, sLRP-1 and visfatin levels in the observation group were significantly higher than those in the control group (P < 0.05). The plasma TC and TG levels in the experimental group were higher than those in the control group, while HDL-C level was lower than that of the control group (P < 0.05). The level of FS in experimental group was significantly higher than those in control group, LVDd was larger, while LVEF was significantly lower than that in the control group (P < 0.05). Receiver operating characteristic (ROC) curve results showed that the area under the curve (AUC) of plasma Lp-PLA2 in predicting the high risk of coronary heart disease was 0.669, and the optimal critical value was 47.36 μg/L. The AUC of serum sLRP-1 in predicting the high risk of coronary heart disease was 0.957, and the optimal critical value was 2.58 μg/mL. The AUC of serum visfatin in predicting the high risk of coronary heart disease was 0.932, and the optimal critical value was 53.46 ng/mL (P < 0.05). Plasma Lp-PLA2, sLRP-1 and visfatin levels in non-remission group were significantly higher than those in the remission group (P < 0.05). Logistic regression equation showed that plasma Lp-PLA2, sLRP-1 and visfatin were positively correlated with treatment outcomes (P < 0.05).
Conclusion Patients with higher plasma levels of Lp-PLA2, sLRP-1 and visfatin have poor response to enhanced external counterpulsation therapy.

FullText(HTML)

References (16)

References

[1]	赵惟超, 裘淼涵, 李晶, 等. 植入新型生物可降解涂层药物洗脱支架后应用双联抗血小板治疗冠心病合并分叉病变患者临床有效性及安全性分析[J]. 临床军医杂志, 2020, 48(5): 485-488. https://www.cnki.com.cn/Article/CJFDTOTAL-JYGZ202005003.htm
[2]	王新成, 郭游行, 惠会婷, 等. 血浆Lp-pLA2、cTnI、HCY水平与冠心病合并高脂血症患者冠脉病变程度的相关性研究[J]. 实用预防医学, 2019, 26(2): 208-210. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYY201902025.htm
[3]	KHORLAMPENKO A A, KARETNIKOVA V N, KOCHERGINA A M, et al. Effect of empagliflosin on renal filtration in patients with coronary heart disease undergoing percutaneous coronary intervention[J]. Kardiologiia, 2020, 60(6): 825.
[4]	汪丽, 郑观芸, 李敏. STEMI患者PCI术后血清血管性血友病因子裂解酶与血浆鸢尾素的水平变化[J]. 山东医药, 2019, 59(28): 55-59. doi: 10.3969/j.issn.1002-266X.2019.28.014
[5]	谭永锦, 谭锦业, 苏小红, 等. 增强型体外反搏对冠心病支架置入术后患者心肌微循环阻力的影响[J]. 中国心血管病研究, 2019, 17(5): 431-435. doi: 10.3969/j.issn.1672-5301.2019.05.011
[6]	国家卫生计生委合理用药专家委员会, 中国药师协会. 冠心病合理用药指南(第2版)[J]. 中国医学前沿杂志: 电子版, 2018, 10(6): 7-136.
[7]	谭晓燕, 许连军, 宋莹, 等. 冠心病介入术后性别对双联抗血小板治疗患者血小板反应性的影响[J]. 中国分子心脏病学杂志, 2020, 110(1): 37-41. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGFB202001009.htm
[8]	KADRY M, ZAHRAN F M, EMRAN T M, et al. The diagnostic accuracy of cardiac enzymes-lipid profile ratio for diagnosing coronary heart disease in chest pain patients[J]. Open Biochem J, 2021, 15(1): 20-25. doi: 10.2174/1874091X02115010020
[9]	崔小豪, 杨志明. 中性粒细胞明胶酶相关脂质运载蛋白在冠心病中的研究进展[J]. 中国全科医学, 2020, 23(27): 3492-3495, 3502. doi: 10.12114/j.issn.1007-9572.2020.00.096
[10]	张爱爱, 韩伟, 宋建英, 等. 血浆脂蛋白相关磷脂酶A2浓度与不同类型冠心病相关性研究[J]. 心肺血管病杂志, 2020, 39(2): 139-142.
[11]	韩海莉, 刘东升, 贾子雷, 等. 血清Lp-PLA2、Hcy及hs-CRP与围绝经期冠心病患者冠状动脉病变严重程度的关系[J]. 河北医科大学学报, 2019, 40(3): 268-271, 276. doi: 10.3969/j.issn.1007-3205.2019.03.005
[12]	田雅楠, 胡娜, 宋海玖, 等. 急性冠脉综合征患者血浆可溶性低密度脂蛋白受体相关蛋白1、调解活化正常T细胞表达和分泌趋化因子浓度的变化及意义[J]. 中国综合临床, 2020, 36(3): 202-206. doi: 10.3760/cma.j.cn121361-20190808-00030
[13]	LUO J, LE CESSIE S, VAN HEEMST D, et al. Diet-derived circulating antioxidants and risk of coronary heart disease: a Mendelian randomization study[J]. J Am Coll Cardiol, 2021, 77(1): 45-54. doi: 10.1016/j.jacc.2020.10.048
[14]	KIVINEN P, SULKAVA R, HALONEN P, et al. Coronary heart disease mortality trends during 50 years as explained by risk factor changes: the European cohorts of the seven countries study[J]. Eur J Prev Cardiol, 2019, 51(12): 1250-1252.
[15]	韩梅, 张驰, 关秀军, 等. 不同类型心绞痛患者血清内脏脂肪素与超敏C反应蛋白、肿瘤坏死因子α的相关性及诊断价值分析[J]. 中国综合临床, 2019, 35(3): 212-217. doi: 10.3760/cma.j.issn.1008-6315.2019.03.005
[16]	刘贞, 赵佳佳, 樊俊雅, 等. 增强型体外反搏对不稳定型心绞痛患者血管内皮舒张功能及血浆脂蛋白磷脂酶A2水平的影响[J]. 实用医学杂志, 2019, 35(3): 437-439. doi: 10.3969/j.issn.1006-5725.2019.03.023

[1]	SHEN Yanmei, LI Huifang, LI Ya, YANG Chaoju. Relationship between serum adipokine expression and insulin resistance in people with different degrees of impaired glucose tolerance and its value in predicting risk of disease progression in prediabetes[J]. Journal of Clinical Medicine in Practice, 2024, 28(23): 116-120, 131. DOI: 10.7619/jcmp.20242935
[2]	XU Meijie, QIAN Wenxia, XU Meihua, ZHANG Xun. Correlation between lipoprotein-associated phospholipase A2 level and cardiovascular disease in patients with obstructivesleep apnea syndrome[J]. Journal of Clinical Medicine in Practice, 2023, 27(3): 6-10. DOI: 10.7619/jcmp.20223291
[3]	LIN Ningning, ZHAO Jiajia, FAN Junya, TIAN Xinyu, ZHANG Hui. Effects of three therapeutic schedules on cardiac functionand prognosis in patients undergoing percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2022, 26(16): 66-70. DOI: 10.7619/jcmp.20220829
[4]	LIU Mingtao, PANG Yanrong, ZHAO Liang, WEN Zhongzheng, HOU Guoqing. Expression and clinical significance of microRNA-210 and lipoprotein-associated phospholipase A2 in patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2021, 25(21): 39-42. DOI: 10.7619/jcmp.20212085
[5]	ZHOU Bing, QIN Yahong, JIAO Yungen. Study on correlation between the expression level of lectin-like oxidized low-density lipoprotein receptor-1 in serum and stability of carotid plaque[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 41-44. DOI: 10.7619/jcmp.202010010
[6]	SONG Laichun. Quality method versus enzyme activity method in detection of serum lipoprotein-associated phospholipase A2 in cardiovascular and cerebrovascular diseases[J]. Journal of Clinical Medicine in Practice, 2019, 23(20): 70-73. DOI: 10.7619/jcmp.201920019
[7]	QIU Min, XU Shaohua, JIANG Hai, LONG Mingzhi. Changes of lipoprotein-associated phospholipase A2 and high sensitivity C reactive protein in patients with coronary slow flow[J]. Journal of Clinical Medicine in Practice, 2019, 23(10): 29-32. DOI: 10.7619/jcmp.201910009
[8]	GU Weixia, XU Jun, ZHUANG Zhiqing, YE Xingrong, WANG Molan, ZHU Jun. Clinical effect of ginkgo leaf tablets on clinical outcomesof patients with forgotten-type mild cognitive impairment and its effect on soluble receptor for advanced glycation end products and soluble low-density lipoprotein receptor-associated protein 1[J]. Journal of Clinical Medicine in Practice, 2017, (24): 27-29,33. DOI: 10.7619/jcmp.201724008
[9]	CAI Guodong, GU Yang, LIU Shengshan, ZHU Hairong. Change and significance of plasma lipoprotein-associated phospholipase A2 and Lipoprotein(a)levels in atherosclerotic cerebral infraction[J]. Journal of Clinical Medicine in Practice, 2014, (16): 18-21. DOI: 10.7619/jcmp.201416005
[10]	PAN Min, LI Benling, YU Xianzhen. Nursing for acute myocardial infarction patients treated with intra-aortic balloon counterpulsation[J]. Journal of Clinical Medicine in Practice, 2013, (20): 15-17. DOI: 10.7619/jcmp.201320005

Cited By

Cited by

Periodical cited type(2)

1.	陈维平，谢芸. Hp感染对高血压患者血管内皮损伤及微炎症反应的影响观察. 中国医学创新. 2022(15): 136-139 .
2.	杨苹，黄冠华. 高血压人群中幽门螺杆菌感染与颈动脉粥样硬化的关系. 内蒙古医学杂志. 2022(05): 530-536 .

Other cited types(2)

Get Citation

PDF

XML

Article views (227) PDF downloads (19) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Relationships of indicators such as level of plasma lipoprotein-associated phospholipase A2 with effect of extracorporeal counterpulsation therapy in high-risk patients with coronary heart disease